The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
|
|---|---|
| Published in |
Frontiers in endocrinology, July 2018
|
| DOI | 10.3389/fendo.2018.00412 |
| Pubmed ID | |
| Authors |
Eugene Han, Eugene Shin, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha |
| Abstract |
Although both sodium glucose co-transporter 2 inhibition by dapagliflozin and thiazolidinedione, pioglitazone have glucose-lowering and anti-inflammatory effects, the therapeutic efficacy of their combination on diabetic nephropathy has not been investigated. 9-week-old male db/db mice were randomly assigned to 4 groups and administrated with (1) vehicle, (2) dapagliflozin, (3) pioglitazone, or (4) dapagliflozin and pioglitazone combination. Human proximal tubule (HK-2) cells were treated with glucose or palmitate acid in the presence of medium, dapagliflozin, pioglitazone, or both. Glomerular tuft area and mesangial expansion of the kidney more reduced in the combination group compared to control and single therapy groups. Podocyte foot process width and glomerular basement membrane thickness decreased regardless of treatment, while the combination group showed the slowest renal hypertrophy progression (P < 0.05). The combination treatment decreased MCP-1, type I and IV collagen expression in the renal cortex. Only the combination treatment decreased the expression of angiotensinogen, IL-6, and TGF-β while it enhanced HK-2 cell survival (all P < 0.05). In conclusion, dapagliflozin and pioglitazone preserved renal function, and combination therapy showed the greatest benefit. These findings suggest that the combination therapy of dapagliflozin with pioglitazone is more effective than the single therapy for preventing the progression of nephropathy in patients with type 2 diabetes. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 13% |
| Peru | 1 | 4% |
| Korea, Republic of | 1 | 4% |
| Unknown | 18 | 78% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 74% |
| Science communicators (journalists, bloggers, editors) | 2 | 9% |
| Practitioners (doctors, other healthcare professionals) | 2 | 9% |
| Scientists | 2 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 20% |
| Researcher | 5 | 13% |
| Student > Bachelor | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 13 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 28% |
| Biochemistry, Genetics and Molecular Biology | 4 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Nursing and Health Professions | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 18 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2018.
All research outputs
#2,747,102
of 25,385,509 outputs
Outputs from Frontiers in endocrinology
#736
of 13,021 outputs
Outputs of similar age
#53,671
of 340,393 outputs
Outputs of similar age from Frontiers in endocrinology
#25
of 212 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,021 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,393 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.